Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
21
10
2019
accepted:
26
05
2020
revised:
12
05
2020
pubmed:
23
6
2020
medline:
1
4
2021
entrez:
23
6
2020
Statut:
ppublish
Résumé
The "watch-and-wait" approach is a common treatment option amongst patients with locally advanced rectal cancer (LARC). However, the diagnostic sensitivity of clinical modalities, such as colonoscopy and magnetic resonance imaging to determine pathological response, is not high. We analysed the clinical utility of circulating tumour DNA (ctDNA) of patients with LARC to predict response to preoperative therapy and postoperative recurrence. A serial ctDNA analysis of 222 plasma samples from 85 patients with LARC was performed using amplicon-based deep sequencing on a cell-free DNA panel covering 14 genes with over 240 hotspots. ctDNA was detected in 57.6% and 22.3% of samples at baseline and after preoperative treatment, respectively, which was significantly different (P = 0.0003). Change in ctDNA was an independent predictor of complete response to preoperative therapy (P = 0.0276). In addition, postoperative ctDNA and carcinoembryonic antigen (CEA) were independent prognostic markers for risk of recurrence after surgery (ctDNA, P = 0.0127 and CEA, P = 0.0105), with a combined analysis having cumulative effects on recurrence-free survival (P = 1.0 × 10 Serial ctDNA analysis may offer clinically useful predictive and prognostic markers for response to preoperative therapy and postoperative recurrence in patients with LARC.
Sections du résumé
BACKGROUND
The "watch-and-wait" approach is a common treatment option amongst patients with locally advanced rectal cancer (LARC). However, the diagnostic sensitivity of clinical modalities, such as colonoscopy and magnetic resonance imaging to determine pathological response, is not high. We analysed the clinical utility of circulating tumour DNA (ctDNA) of patients with LARC to predict response to preoperative therapy and postoperative recurrence.
METHODS
A serial ctDNA analysis of 222 plasma samples from 85 patients with LARC was performed using amplicon-based deep sequencing on a cell-free DNA panel covering 14 genes with over 240 hotspots.
RESULTS
ctDNA was detected in 57.6% and 22.3% of samples at baseline and after preoperative treatment, respectively, which was significantly different (P = 0.0003). Change in ctDNA was an independent predictor of complete response to preoperative therapy (P = 0.0276). In addition, postoperative ctDNA and carcinoembryonic antigen (CEA) were independent prognostic markers for risk of recurrence after surgery (ctDNA, P = 0.0127 and CEA, P = 0.0105), with a combined analysis having cumulative effects on recurrence-free survival (P = 1.0 × 10
CONCLUSIONS
Serial ctDNA analysis may offer clinically useful predictive and prognostic markers for response to preoperative therapy and postoperative recurrence in patients with LARC.
Identifiants
pubmed: 32565539
doi: 10.1038/s41416-020-0941-4
pii: 10.1038/s41416-020-0941-4
pmc: PMC7462982
doi:
Substances chimiques
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-810Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18K08664
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 18K08635
Références
Cedermark, B., Dahlberg, M., Glimelius, B., Pahlman, L., Rutqvist, L. E. & Wilking, N. Improved survival with preoperative radiotherapy in resectable rectal cancer. N. Engl. J. Med. 336, 980–987 (1997).
doi: 10.1056/NEJM199704033361402
Kapiteijn, E., Marijnen, C. A., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638–646 (2001).
doi: 10.1056/NEJMoa010580
Peeters, K. C., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246, 693–701 (2007).
doi: 10.1097/01.sla.0000257358.56863.ce
Das, P., Skibber, J. M., Rodriguez-Bigas, M. A., Feig, B. W., Chang, G. J., Wolff, R. A. et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109, 1750–1755 (2007).
doi: 10.1002/cncr.22625
Silberfein, E. J., Kattepogu, K. M., Hu, C. Y., Skibber, J. M., Rodriguez-Bigas, M. A., Feig, B. et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann. Surg. Oncol. 17, 2863–2869 (2010).
doi: 10.1245/s10434-010-1119-8
Smith, K. D., Tan, D., Das, P., Chang, G. J., Kattepogu, K., Feig, B. W. et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann. Surg. 251, 261–264 (2010).
doi: 10.1097/SLA.0b013e3181bdfc27
Habr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Silva e Sousa, A. H. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Ann Surg. 240, 711–718 (2004).
doi: 10.1097/01.sla.0000141194.27992.32
Restivo, A., Zorcolo, L., Cocco, I. M., Manunza, R., Margiani, C., Marongiu, L. et al. Elevated CEA levels and low distance of the tumor from the anal verge are predictors of incomplete response to chemoradiation in patients with rectal cancer. Ann. Surg. Oncol. 20, 864–871 (2013).
doi: 10.1245/s10434-012-2669-8
Garland, M. L., Vather, R., Bunkley, N., Pearse, M. & Bissett, I. P. Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Int. J. Colorectal Dis. 29, 301–307 (2014).
doi: 10.1007/s00384-013-1821-7
Russo, A. L., Ryan, D. P., Borger, D. R., Wo, J. Y., Szymonifka, J., Liang, W. Y. et al. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J. Gastrointest. Cancer 45, 34–39 (2014).
doi: 10.1007/s12029-013-9546-y
Bitterman, D. S., Resende Salgado, L., Moore, H. G., Sanfilippo, N. J., Gu, P., Hatzaras, I. et al. Predictors of complete response and disease recurrence following chemoradiation for rectal cancer. Front. Oncol. 5, 286 (2015).
doi: 10.3389/fonc.2015.00286
Smith, F. M., Wiland, H., Mace, A., Pai, R. K. & Kalady, M. F. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis. Colon Rectum 57, 311–315 (2014).
doi: 10.1097/DCR.0b013e3182a84eba
van den Broek, J. J., van der Wolf, F. S., Lahaye, M. J., Heijnen, L. A., Meischl, C., Heitbrink, M. A. et al. Accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation. Dis. Colon Rectum 60, 274–283 (2017).
doi: 10.1097/DCR.0000000000000743
Liu, S., Zhong, G. X., Zhou, W. X., Xue, H. D., Pan, W. D., Xu, L. et al. Can endorectal ultrasound, MRI, and mucosa integrity accurately predict the complete response for mid-low rectal cancer after preoperative chemoradiation? A prospective observational study from a single medical center. Dis. Colon Rectum 61, 903–910 (2018).
doi: 10.1097/DCR.0000000000001135
Osumi, H., Shinozaki, E., Takeda, Y., Wakatsuki, T., Ichimura, T., Saiura, A. et al. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Med. 8, 408–417 (2019).
doi: 10.1002/cam4.1913
Husain, H. & Velculescu, V. E. Cancer DNA in the circulation: the liquid biopsy. J. Am. Med. Assoc. 318, 1272–1274 (2017).
doi: 10.1001/jama.2017.12131
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715–1722 (2015).
doi: 10.1093/annonc/mdv177
Nakamura, Y. & Yoshino, T. Clinical utility of analyzing circulating tumor DNA in patients with metastatic colorectal cancer. Oncologist 23, 1310–1318 (2018).
doi: 10.1634/theoncologist.2017-0621
Thomsen, C. B., Hansen, T. F., Andersen, R. F., Lindebjerg, J., Jensen, L. H. & Jakobsen, A. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma. J. Exp. Clin. Cancer Res. 37, 55 (2018).
doi: 10.1186/s13046-018-0723-5
Schou, J. V., Larsen, F. O., Sorensen, B. S., Abrantes, R., Boysen, A. K., Johansen, J. S. et al. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer. Ann. Oncol. 29, 610–615 (2018).
doi: 10.1093/annonc/mdx778
Habr-Gama, A., Sabbaga, J., Gama-Rodrigues, J., Sao Juliao, G. P., Proscurshim, I., Bailao Aguilar, P. et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis. Colon Rectum 56, 1109–1117 (2013).
doi: 10.1097/DCR.0b013e3182a25c4e
Chino, A., Konishi, T., Ogura, A., Kawachi, H., Osumi, H., Yoshio, T. et al. Endoscopic criteria to evaluate tumor response of rectal cancer to neoadjuvant chemoradiotherapy using magnifying chromoendoscopy. Eur. J. Surg. Oncol. 44, 1247–1253 (2018).
doi: 10.1016/j.ejso.2018.04.013
Dworak, O., Keilholz, L. & Hoffmann, A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 12, 19–23 (1997).
doi: 10.1007/s003840050072
Shin, S., Kim, Y., Chul Oh, S., Yu, N., Lee, S. T., Rak Choi, J. et al. Validation and optimization of the ion torrent S5 XL sequencer and oncomine workflow for BRCA1 and BRCA2 genetic testing. Oncotarget 8, 34858–34866 (2017).
doi: 10.18632/oncotarget.16799
Xu, C. A review of somatic single nucleotide variant calling algorithms for next-generation sequencing data. Comput Struct. Biotechnol. J. 16, 15–24 (2018).
doi: 10.1016/j.csbj.2018.01.003
Wasserberg, N. Interval to surgery after neoadjuvant treatment for colorectal cancer. World J. Gastroenterol. 20, 4256–4262 (2014).
doi: 10.3748/wjg.v20.i15.4256
Chow, O. S., Kuk, D., Keskin, M., Smith, J. J., Camacho, N., Pelossof, R. et al. KRAS and combined KRAS/TP53 mutations in locally advanced rectal cancer are independently associated with decreased response to neoadjuvant therapy. Ann. Surg. Oncol. 23, 2548–2555 (2016).
doi: 10.1245/s10434-016-5205-4
Habr-Gama, A., Perez, R. O., Wynn, G., Marks, J., Kessler, H. & Gama-Rodrigues, J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis. Colon Rectum 53, 1692–1698 (2010).
doi: 10.1007/DCR.0b013e3181f42b89
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).
doi: 10.1126/scitranslmed.aaf6219
Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K. et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut 68, 663–671 (2019).
doi: 10.1136/gutjnl-2017-315852
Naccarati, A., Polakova, V., Pardini, B., Vodickova, L., Hemminki, K., Kumar, R. et al. Mutations and polymorphisms in TP53 gene–an overview on the role in colorectal cancer. Mutagenesis 27, 211–218 (2012).
doi: 10.1093/mutage/ger067
Lane, D. P. Cancer. p53, guardian of the genome. Nature 358, 15–16 (1992).
doi: 10.1038/358015a0
Merritt, A. J., Potten, C. S., Kemp, C. J., Hickman, J. A., Balmain, A., Lane, D. P. et al. The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res. 54, 614–617 (1994).
pubmed: 8306319
Spitz, F. R., Nguyen, D., Skibber, J. M., Meyn, R. E., Cristiano, R. J. & Roth, J. A. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin. Cancer Res. 2, 1665–1671 (1996).
pubmed: 9816114
Sakai, K., Kazama, S., Nagai, Y., Murono, K., Tanaka, T., Ishihara, S. et al. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget 5, 9641–9649 (2014).
doi: 10.18632/oncotarget.2438
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
doi: 10.1038/nature11252
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33, 125–136 (2018).
doi: 10.1016/j.ccell.2017.12.004
Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006).
doi: 10.1126/science.1133427